Arakis, Vectura Enter Potential $375M Novartis Deal For AD 237 
10/19/2005 5:13:13 PM

LONDON - Two UK companies with a jointly developed product signed one of the biggest deals to date in European biotechnology, agreeing to a potential $375 million license with Novartis AG for their treatment of chronic obstructive pulmonary disease (COPD).